Dihydrofolate reductase inhibitors: Developments in antiparasitic chemotherapy

Expert Opinion on Therapeutic Patents

Volumn 18, Issue 2, 2008, Pages 143-157

  Bolstad, David B ^a   Bolstad, Erin S D ^a   Wright, Dennis L ^a   Anderson, Amy C ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Antifolate; Antiprotozoal; DHFR; Diaminopyrimidine; Malaria; Parasitic diseases

Indexed keywords

2,4 DIAMINOPYRIMIDINE DERIVATIVE; 4,6 DIAMINO 1,2 DIHYDRO 2,2 DIMETHYL 1 [3 (2,4,5 TRICHLOROPHENOXY)PROPOXY] 1,3,5 TRIAZINE; ANTIMALARIAL AGENT; ANTIPARASITIC AGENT; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; BICYCLO[4.3.0]NONANE INHIBITOR; CHLORPROGUANIL PLUS DAPSONE; COTRIMOXAZOLE; CYCLOGUANIL; DECALIN DERIVATIVE; DIAMINOTRIAZINE; DIHYDROFOLATE REDUCTASE; DIHYDROFOLATE REDUCTASE INHIBITOR; DIHYDROPTEROATE SYNTHASE INHIBITOR; FANSIDAR; FURO[2,3 D]PYRIMIDINE DERIVATIVE; METAKELFIN; N [3 (2,4,5 TRICHLOROPHENOXY)PROPOXY] N' ISOPROPYLIMIDOCARBONIMIDIC DIAMIDE; PIRITREXIM; PRIMAQUINE; PROGUANIL; PS 26; PS 33; PYRIMETHAMINE; PYRIMETHAMINE SULFADIAZINE; PYRROLO[2,3 D]PYRIMIDINE DERIVATIVE; TRIMETHOPRIM; TRIMETHOPRIM DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AFRICAN TRYPANOSOMIASIS; ANTIMALARIAL ACTIVITY; BINDING AFFINITY; CHAGAS DISEASE; CLINICAL TRIAL; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM HOMINIS; CRYSTAL STRUCTURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; GASTROINTESTINAL TOXICITY; HUMAN; IC 50; LEISHMANIA MAJOR; LEISHMANIASIS; MALARIA; MALARIA FALCIPARUM; MULTIDRUG RESISTANCE; NONHUMAN; PARASITOSIS; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; RELAPSE; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TESTIS ATROPHY; TOXOPLASMA GONDII; TOXOPLASMOSIS; TRYPANOSOMA CRUZI;

EID: 40749132562     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.18.2.143     Document Type: Review

References (78)

1. Greenwood B, Mutabingwa T. Malaria in 2002. Nature 2002;415:670-2
2. Sachs J, Malaney P. The economic and social burden of malaria. Nature 2002;415:680-5
3. Hyde J. Exploring the folate pathway in Plasmodium falciparum. Acta Tropica 2005;94:191-206
4. Nzila A. The past, present and future of antifolates in the treatment of Plasmodium falciparum infection. J Antimicrob Chemother 2006;57:1043-54
5. Gangjee A, Yu J, Copper JE, Smith CD. Discovery of novel antitumor antimitotic agents that also reverse tumor resistance. J Med Chem 2007;50(14):3290-301
6. Klepser M, Klepser T. Drug treatment of HIV-related opportunistic infections. Drugs 1997;53:40-73
7. Aspinall T, Joynson D, Guy E, et al. The molecular basis of sulfonamide resistance in Toxoplasma gondii and implications for the clinical management of toxoplasmosis. J Infect Dis 2002;185:1637-43
8. Gregson A, Plowe C. Mechanisms of resistance of malaria parasites to antifolates. Pharmacol Rev 2005;57:117-45
9. Looareesuwan S. Harinasuta T, Chongsuphajaisiddhi T. Drug resistant malaria, with special reference to Thailand. Southeast Asian J Trop Med Public Health 1992;23:621-34
10. Wang P, Lee C, Bayoumi R, et al. Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthase and dihydrofolate reductase alleles in a large number of field samples of diverse origins. Mol Biochem Parasitol 1997;89:161-77
11. Sirawaraporn W, Sathitkul T, Sirawaraporn R, et al. Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc Natl Acad Sci USA 1997;94:1124-9
12. Yuvaniyama J, Chitnumsub P, Kamchonwongpaisan S, et al. Insights into antifolate resistance from malarial DHFR-TS structures. Nat Struct Biol 2003;10:357-65
13. Canfield C, Milhous W, Ager A, et al. PS-15: a potent, orally active antimalarial from a new class of folic acid antagonists. Am J Trop Med Hyg 1993;49:121-6
14. Rieckmann K, Yeo A, Edstein M. Activity of PS-15 and its metabolite, WR99210, against Plasmodium falciparum in an in vivo-in vitro model. Trans R Soc Trop Med Hyg 1996;90:568-71
15. Jensen N, Ager A, Bliss R, et al. Phenoxypropoxybiguanides, prodrugs of DHFR-inhibiting diaminotriazine antimalarials. J Med Chem 2001;44:3925-31
16. Alloueche A, Bailey W, Barton S, et al. Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial. Lancet 2004;363:1843-8
17. Anderson A. Two crystal structures of dihydrofolate reductase-thymidylate synthase from cryptosporidium hominis reveal protein:ligand interactions including a structural basis for observed antifolate resistance. Acta Cryst 2005;F61:258-62
18. O'Neil R, Lilien R, Donald B, et al. Phylogenetic classification of protozoa based on the structure of the linker domain in the bifunctional enzyme, dihydrofolate reductase-thymidylate synthase. J Biol Chem 2003;278:52980-7
19. O'Neil R, Lilien R, Donald B, et al. The crystal structure of dihydrofolate reductase-thymidylate synthase from cryptosporidium hominis reveals a novel architecture for the bifunctional enzyme. J Eukaryot Microbiol 2003;50 Suppl:555-6
20. Pelphrey P, Popov V, Joska T, et al. Highly efficient ligands for DHFR from Cryptosporidium hominis and Toxoplasma gondii inspired by structural analysis. J Med Chem 2007;50:940-50
21. Knighton D, Kan C, Howland E, et al. Structure of and kinetic channeling in bifunctional dihydrofolate reductase-thymidylate synthase. Nat Struct Biol 1994;1:186-94
22. Dana Farber Cancer Institute. US7119095 (2006)
23. Dana Farber Cancer Institute. US7056911 (2006)
24. Rosowsky & Forsch. US20060142315 (2006)
25. Rosowsky A, Forsch RA, Queener SF. Inhibition of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductases by 2,4-diamino-5-[2-methoxy-5-(omega-carboxyalkyloxy)benzyl]pyrimidines: marked improvement in potency relative to trimethoprim and species selectivity relative to piritrexim. J Med Chem 2002;45(1):233-41
26. Rosowsky A, Forsch RA, Queener SF. Further studies on 2,4-diamino-5-(2′,5′-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS. J Med Chem 2003;46(9):1726-36
27. Dana Farber Cancer Institute. WO2004082613; 2004
28. Chan DC, Laughton CA, Queener SF, Stevens MF. Structural studies on bioactive compounds. 34. Design, synthesis, and biological evaluation of triazenyl-substituted pyrimethamine inhibitors of Pneumocystis carinii dihydrofolate reductase. J Med Chem 2001;44(16):2555-64
29. British Technology Group Ltd. US5618928; 1997
30. Stevens MF, Philip KS, Rathbone DL, et al. Structural studies on bioactive compounds. 28. Selective activity of triazenyl-substituted pyrimethamine derivatives against Pneumocystis carinii dihydrofolate reductase. J Med Chem 1997;40(12):1886-93
31. Tarnchompoo B, Sirichaiwat C, Phupong W, et al. Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum. J Med Chem 2002;45(6):1244-52
32. Kamchonwongpaisan S, Quarrell R, Chareonsethakul N, et al. Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities. J Med Chem 2004;47:673-80
33. National Science and Technology Development Agency US20040180913; 2004
34. Kamchonwongpaisan S, Quarrell R, Charoensetakul N, et al. Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities. J Med Chem 2004;47(3):673-80
35. Yuthavong Y, Vilaivan T, Chareonsethakul N, et al. Development of a lead inhibitor for the A16V+S108T mutant of dihydrofolate reductase from the cycloguanil-resistant strain (T9/94) of Plasmodium falciparum. J Med Chem 2000;43(14):2738-44
36. Lowe. WO2001053276 (2001)
37. Jacobus Pharmaceutical Co., Inc. US6551614 (2003)
38. Jacobus Pharmaceutical Co., Inc. US6693217; 2004
39. Jacobus Pharmaceutical Co., Inc. US7256218 (2007)
40. Glaxo Wellcome, Inc. US6166046 (2000)
41. Smithkline Beecham Corp. US6413993 (2002)
42. Chan DC, Fu H, Forsch RA, et al. Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with omega-carboxyalkoxy or omega-carboxy-1-alkynyl substitution in the side chain. J Med Chem 2005;48(13):4420-31
43. Dana Farber Cancer Institute. US7256197 (2007)
44. Rosowsky A, Cody V, Galitsky N, et al. Structure-based design of selective inhibitors of dihydrofolate reductase: synthesis and antiparasitic activity of 2, 4-diaminopteridine analogues with a bridged diasylamine side chain. J Med Chem 1999;42(23):4853-60
45. Cody V, Galitsky N, Luft JR, et al. Structure-based enzyme inhibitor design: modeling studies and crystal structure analysis of Pneumocystis carinii dihydrofolate reductase ternary complex with PT653 and NADPH. Acta Crystallogr D Biol Crystallogr 2002;58(6 Pt 2):946-54
46. Dana Farber Cancer Institute. WO2003031458 (2003)
47. Rosowsky A, Chen H, Fu H, Queener S. Synthesis of new 2,4-diaminopyrido[2,3-d] pyrimidine and 2,4-diaminopyrrolo[2,3-d] pyrimidine inhibitors of Pneumocystis carinii, Toxoplasma gondii and Mycobacterium avium dihydrofolate reductase. Bioorg Med Chem 2003;11:59-67
48. Gangjee A, Adair O, Queener S. Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl) pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents. J Med Chem 2003;46:5074-82
49. Gangjee A, Devraj R, Queener S. Synthesis and dihydrofolate reductase inhibitory activity of 2,4-diamino-5-deaza and 2,4-diamino-5,10-dideaza lipophilic antifolates. J Med Chem 1997;40:470-8
50. Duquesne Univ. of the Holy Ghost. US5346900 (1994)
51. Duquesne Univ. of the Holy Ghost. US5508281 (1996)
52. Duquesne Univ. of the Holy Ghost. US5736547 (1998)
53. Duquesne Univ. of the Holy Ghost. 5866580 (1999)
54. Duquesne Univ. of the Holy Ghost. US6114339 (2000)
55. Duquesne Univ. of the Holy Ghost. US6696455 B1 (2004)
56. Duquesne Univ. of the Holy Ghost. US5863920 (1999)
57. Duquesne Univ. of the Holy Ghost. US5958930 (1999)
58. Duquesne Univ. of the Holy Ghost. US6096750 (2000)
59. Duquesne Univ. of the Holy Ghost. US6962920 (2005)
60. Gangjee A, Devraj R, McGuire JJ, et al. Classical and nonclassical furo[2,3-d] pyrimidines as novel antifolates: synthesis and biological activities. J Med Chem 1994;37(8):1169-76
61. Gangjee A, Yu J, McGuire J, et al. Design, synthesis and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent. J Med Chem 2000;43:3837-51
62. Gangjee A, Guo X, Queener SF, et al. Selective Pneumocystis carinii dihydrofolate reductase inhibitors: design, synthesis, and biological evaluation of new 2,4-diamino-5-substituted-furo[2,3-d] pyrimidines. J Med Chem 1998;41(8):1263-71
63. Gangjee A, Zeng Y, McGuire JJ, Kisliuk RL. Effect of C9-methyl substitution and C8-C9 conformational restriction on antifolate and antitumor activity of classical 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines. J Med Chem 2000;43(16):3125-33
64. Duquesne Univ. of the Holy Ghost. US6077844 (2000)
65. Duquesne Univ. of the Holy Ghost. US6420370 (2002)
66. Duquesne Univ. of the Holy Ghost. US5877178 (1999)
67. Duquesne Univ. of the Holy Ghost. US5939420 (1999)
68. Duquesne Univ. of the Holy Ghost. US6221872 (2001)
69. Gangjee A, Mavandadi F, Queener S. Effect of N9-methylation and bridge atom variation on the activity of 5-substituted 2,4-diaminopyrrolo[2,3-d] pyrimidines against dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii. J Med Chem 1997;40:1173-7
70. Gangjee A, Mavandadi F, Queener S. McGuire J. Novel 2,4-diamino-5-substituted-pyrrolo[2,3-d]pyrimidines as classical and nonclassical antifolate inhibitors of dihydrofolate reductases. J Med Chem 1995;38:2158-65
71. Gangjee A, Lin X, Queener SF. Design, synthesis, and biological evaluation of 2,4-diamino-5-methyl-6-substituted-pyrrolo [2,3-d]pyrimidines as dihydrofolate reductase inhibitors. J Med Chem 2004;47(14):3689-92
72. Gangjee A, Lin X, Kisliuk RL, McGuire JJ. Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo [2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d] pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofolate reductase and thymidylate synthase and as potential antitumor agents. J Med Chem 2005;48(23):7215-22
73. Duquesne Univ. of the Holy Ghost. US6103727 (2000)
74. Gangjee A, Vidwans A, Elzein E, et al. Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines. J Med Chem 2001;44(12):1993-2003
75. Gangjee A, Mavandadi F, Kisliuk RL, et al. 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines as nonclassical antifolate inhibitors of thymidylate synthase. J Med Chem 1996;39(23):4563-8
76. Duquesne Univ. of the Holy Ghost. US6537999; 2003
77. Gangjee A, Yu J, McGuire JJ, et al. Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent. J Med Chem 2000;43(21):3837-51
78. Duquesne Univ. of the Holy Ghost. US6518426 (2003)